HRMY

Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds.

In a comparison of two medical-biomedical stocks, Harmony Biosciences Holdings (HRMY) emerges as the superior value option compared to CSL Limited Sponsored ADR (CSLLY). HRMY has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 10.52, and a Value grade of A. CSLLY has a Zacks Rank of #4 (Sell) with a forward P/E of 19.66 and a Value grade of C, making it less attractive to value investors.

Harmony Biosciences (HRMY) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/B ratio of 2.42, P/S ratio of 2.42, and P/CF ratio of 9.34, all favorable compared to industry averages, suggesting the company may be undervalued in the market.